ANALGESIC AND MUSCLE RELAXANT CAPLETS TABLET

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

IBUPROFEN; METHOCARBAMOL

Pieejams no:

TEVA CANADA LIMITED

ATĶ kods:

M03BA53

SNN (starptautisko nepatentēto nosaukumu):

METHOCARBAMOL, COMBINATIONS EXCL PSYCHOLEPTICS

Deva:

200MG; 500MG

Zāļu forma:

TABLET

Kompozīcija:

IBUPROFEN 200MG; METHOCARBAMOL 500MG

Ievadīšanas:

ORAL

Vienības iepakojumā:

18/40

Receptes veids:

OTC

Ārstniecības joma:

CENTRALLY ACTING SKELETAL MUSCLE RELAXANTS

Produktu pārskats:

Active ingredient group (AIG) number: 0248961001; AHFS:

Autorizācija statuss:

CANCELLED POST MARKET

Autorizācija datums:

2021-08-12

Produkta apraksts

1 | P a g e
PRODUCT MONOGRAPH
ANALGESIC & MUSCLE RELAXANT CAPLETS
500 MG METHOCARBAMOL AND 200 MG IBUPROFEN TABLETS
THERAPEUTIC CLASSIFICATION
MUSCLE RELAXANT / ANALGESIC
TEVA CANADA LIMITED
Date of Preparation:
30 Novopharm Court
January 8, 2013
Toronto, Canada
M1B 2K9
Control# 161025
2 | P a g e
TABLE OF CONTENTS
Clinical Pharmacology
..............................................................................................................................
3
Indications:
................................................................................................................................................
7
Contraindications
......................................................................................................................................
8
Warnings:
..................................................................................................................................................
8
Precautions
..............................................................................................................................................
12
Drug Interactions
....................................................................................................................................
13
Adverse Reactions
..................................................................................................................................
15
Symptoms and Treatment of Overdose
...................................................................................................
17
Dosage and
Administration.....................................................................................................................
18
Pharmaceutical Information
....................................................................................................................
19
Composition:
...........................................................................................................................................
21
Availability of Dosage Forms
..........................